The Korean journal of internal medicine

  • 제26권1호
  • /
  • Pages.82-88
  • /
  • 2011
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Safety of Hepatic Arterial Infusion of Fluorouracil with Leucovorin as Salvage Treatment for Refractory Liver Metastases from Colorectal Cancer

  • Lee, Hyun-Jung (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Lee, Yoon-Soo (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Lee, Keun-Wook (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, So-Yeon (Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Yoon, Chang-Jin (Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Shin, Dong-Yeop (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Lee, Yun-Gyoo (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Choi, Se-Yeon (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kang, Sung-Gwon (Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kang, Sung-Bum (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Jee-Hyun (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • 발행 : 2011.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Limited options remain for patients with metastatic colorectal cancer (CRC) after failure of standard systemic chemotherapy. Readministration of chemotherapeutic agents by hepatic arterial infusion (HAI) has the rationale of providing higher concentrations of chemotherapeutic agents to hepatic metastases. The present study was conducted to evaluate the efficacy and safety of HAI of fluorouracil with leucovorin (HAI 5-FU/LV) for patients with liver metastases from CRC. Methods: Fourteen patients with liver metastases from CRC who received HAI 5-FU/LV after failure of systemic chemotherapy containing fluorouracil and leucovorin were identified and their medical records were reviewed. Results: Of 10 patients evaluable for response, one partial response, six stable disease, and three progressive disease were reported. Additionally, the overall response and disease control rates were 7% and 50%, respectively. The median time to progression was 4.3 months (range, 2.9 to 5.6), to hepatic progression was 5.8 months (range, 4.7 to 6.9), and to extrahepatic progression was 5.8 months (range, 2.3 to 9.2). No grade 3/4 hematologic toxicities occurred and one case of abdominal pain and two cases of oral mucositis were the only grade 3 non-hematologic toxicities. Catheter-related complications occurred in three patients: one thrombosis, one infection, and one displacement. Conclusions: HAI 5-FU/LV was well tolerated and showed modest efficacy for patients with liver metastases from refractory CRC. Readministration of previously used chemotherapeutic agents via the hepatic artery could be an effective salvage option and warrants further investigation in a prospective trial.

키워드

참고문헌

  1. Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 1976;2:285-288.
  2. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-165. https://doi.org/10.1016/S0140-6736(05)17706-X
  3. Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med 2005;56:139-156. https://doi.org/10.1146/annurev.med.56.082103.104630
  4. Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007;25:4593-4602. https://doi.org/10.1200/JCO.2007.10.8126
  5. Garufi C, Torsello A, Tumulo S, et al. POCHER (preoperative chemotherapy for hepatic resection) study with cetuximab (C-225) plus chronomodulated (chrono) CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-FFL) in colorectal liver metastases (CLM). J Clin Oncol 2009;27(15S):e15020.
  6. Falcone A, Masi G, Loupakis F, et al. FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): a phase II study by the G.O.N.O. group. J Clin Oncol 2008;26(15S):4031. https://doi.org/10.1200/jco.2008.26.15_suppl.4031
  7. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969-977.
  8. Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet Oncol 2001;2:418-428. https://doi.org/10.1016/S1470-2045(00)00419-8
  9. Hohn DC, Rayner AA, Economou JS, Ignoffo RJ, Lewis BJ, Stagg RJ. Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer 1986;57:465-470. https://doi.org/10.1002/1097-0142(19860201)57:3<465::AID-CNCR2820570311>3.0.CO;2-S
  10. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009;(3):CD007823.
  11. Lorenz M, Müller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18:243-254. https://doi.org/10.1200/JCO.2000.18.2.243
  12. Tanaka T, Arai Y, Inaba Y, et al. Radiologic placement of sidehole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 2003;14:63-68. https://doi.org/10.1097/01.RVI.0000052292.26939.59
  13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. https://doi.org/10.1093/jnci/92.3.205
  14. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947. https://doi.org/10.1200/JCO.2000.18.16.2938
  15. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237. https://doi.org/10.1200/JCO.2004.05.113
  16. Bouchahda M, Tanaka K, Adam R, et al. Hepatic artery chronomodulated infusion of irinotecan, 5-fluorouracil and oxaliplatin against liver metastases in heavily pretreated patients with colorectal cancer. J Clin Oncol 2004;22(14S):3722. https://doi.org/10.1200/jco.2004.22.14_suppl.3722
  17. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008;15:219-226. https://doi.org/10.1245/s10434-007-9581-7
  18. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003;361:368-373. https://doi.org/10.1016/S0140-6736(03)12388-4
  19. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-1403. https://doi.org/10.1200/JCO.2005.03.8166
  20. Bouchahda M, Adam R, Giacchetti S, et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 2009;115:4990-4999. https://doi.org/10.1002/cncr.24549
  21. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002;29:119-125.
  22. Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005;201:57-65. https://doi.org/10.1016/j.jamcollsurg.2005.03.019
  23. Scaife CL, Curley SA, Izzo F, et al. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol 2003;10:348-354. https://doi.org/10.1245/ASO.2003.08.019
  24. Hildebrandt B, Pech M, Nicolaou A, et al. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach. BMC Cancer 2007;7:69. https://doi.org/10.1186/1471-2407-7-69
  25. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-1118. https://doi.org/10.1200/JCO.1992.10.7.1112

피인용 문헌

  1. Hepatic Artery Infusion Pump Combined With Systemic Chemotherapy for Patients With Liver Metastases From Breast Carcinoma vol.20, pp.None, 2011, https://doi.org/10.1177/15330338211051552